Skip to main content

AI within Biopharma: Separating Value from Hype

Tuesday, February 27, 2024
Majestic Complex
OpenAI’s ChatGPT exploded onto the scene in November 2022, attracting 1 million users in 5 days, and now more than 1.5 billion visits per month. It joins the class of AI tools including several used in computational chemistry and drug discovery that the biotechnology industry has been implementing for years, including IPOs of AI-based biotechs. This session will examine the present business cases for which AI applications are showing greatest reliability of returns across the drug development process and which are still too early in the hype cycle.
Swayampakula Ramakanth, Managing Director, Senior Healthcare Analyst - H.C. Wainwright
Zachary Carpenter, Founder and CEO - VantAI
Abe Heifets, CEO & Co-Founder - Atomwise
Petrina Kamya, Vice President and Global Head of AI Platforms, Insilico Medicine - President, Insilico Medicine Canada
Liz Schwarzbach, Chief Business Officer - BigHat Biosciences

Double Helix


Supporting Bank Sponsor


Premier Sponsors

Conference Sponsors


Media Partner


Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.